Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation.
Read the original at TechCrunch ↗
- Topics
- HealthcareMarkets & Investment
- Tracked via
- “that uses AI to”